In a breakthrough that could transform the lives of millions of patients worldwide, MIT engineers have developed a revolutionary method for delivering therapeutic antibodies that replaces lengthy intravenous infusions with simple injections. This innovation promises to dramatically improve treatment accessibility and convenience for patients suffering from cancer, autoimmune disorders, and other chronic conditions.
The Problem with Current Antibody Treatments
Therapeutic antibodies like rituximab have become cornerstone treatments for a wide range of serious medical conditions, including Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, rheumatoid arthritis, and inflammatory bowel disease. However, the current delivery method presents significant challenges for patients.
“Antibody treatments for cancer and other diseases are typically delivered intravenously, because of the large volumes that are needed per dose,” explains Talia Zheng, lead author of the new study and MIT graduate student. “This means the patient has to go to a hospital for every treatment, where they may spend hours receiving the infusion.”
Current IV infusions typically require patients to spend approximately 20-30 minutes for the actual infusion process, followed by an hour of monitoring to ensure no adverse reactions occur. This makes the total treatment time approximately two hours per session, requiring significant time commitments and travel to medical facilities. For elderly patients or those with mobility issues, this can be particularly burdensome.
The Scientific Breakthrough
The MIT team, led by Patrick Doyle, the Robert T. Haslam Professor of Chemical Engineering, has solved a long-standing technical challenge in antibody formulation. Traditional antibody solutions are formulated at low concentrations—between 10 to 30 milligrams of antibody per milliliter of solution. This low concentration requires patients to receive at least 100 milliliters per dose, which is far too large to be injected using a standard syringe.
To decrease the volume to a syringe-appropriate level, the antibody concentration would need to be at least 300 milligrams per milliliter. However, this would make the solution much too thick to be injected safely. “You can’t concentrate existing formulations to these concentrations,” Doyle notes. “They’ll be very viscous and will exceed the force threshold of what you can inject into a patient.”
How the New Technology Works
The MIT researchers developed an innovative approach that creates solid particles of highly concentrated antibodies suspended in solution. Their method involves creating droplets containing antibodies dissolved in a watery solution, which are then suspended in an organic solvent called pentanol. These droplets are dehydrated, leaving behind highly concentrated solid antibodies—at about 360 milligrams of antibody per milliliter of solution.
- The particles include a small amount of polyethylene glycol (PEG) to help stabilize them
- The organic solvent is removed and replaced with an aqueous solution similar to current infusion solutions
- The particles range from about 60 to 200 microns in diameter
- The process can be done rapidly using microfluidic setup
- No centrifugation is required, unlike previous approaches
This revolutionary manufacturing process represents a significant advance over their 2023 work, which required centrifugation—a step that would have been difficult to scale up for manufacturing. The new approach is designed to be simple, scalable, and compatible with GMP (good manufacturing practice) regulations.
Patient Impact and Accessibility
The potential impact on patient care is substantial. With this new technology, only about 2 milliliters of solution would be needed per dose—enough to deliver more than 700 milligrams of the target antibody using a standard 2-milliliter syringe. This represents a more than 50-fold reduction in required volume compared to traditional IV infusions.
“As the global population ages, making the treatment process more convenient and accessible for those populations is something that needs to be addressed,” says Zheng.
- Elderly patients who may have difficulty traveling to hospitals for regular treatments
- Rural patients who live far from specialized medical centers
- Patients with mobility issues who find frequent hospital visits physically challenging
- Working professionals who struggle to take time off for lengthy treatment sessions
- Caregivers who must accompany patients to medical facilities
The researchers tested the injectability of their solution using a mechanical force tester and found that the force needed to push the plunger of a syringe containing the particle solution was less than 20 newtons—less than half of the maximum acceptable force, making it highly injectable.
Manufacturing and Future Prospects
The microfluidic manufacturing process offers significant advantages for scalability. Unlike traditional manufacturing methods that require complex equipment and processes, this approach can be scaled up using emulsification devices that comply with GMP regulations. This makes the technology well-positioned for rapid adoption by pharmaceutical manufacturers.
“Our first approach was a bit brute force,” Doyle explains. “When we were developing this new approach, we said it’s got to be simple if it’s going to be better and scalable.”
The formulations have also demonstrated impressive stability, remaining viable under refrigeration for at least four months—a crucial factor for distribution and storage logistics.
Broad Medical Applications
While the technology has shown promise with rituximab, one of the most widely used therapeutic antibodies, its potential applications extend far beyond this single drug. The approach could be applied to a wide range of therapeutic antibodies used to treat various cancers, autoimmune disorders, and infectious diseases.
The research was funded by the MIT Undergraduate Research Opportunities Program and the U.S. Department of Energy, and the findings were published in the journal Advanced Materials in a paper titled “High-Concentration Antibody Formulation via Solvent-Based Dehydration.”
Looking Forward
The MIT team is now planning to test their antibody particles for therapeutic applications in animal models and working on scaling up the manufacturing process for large-scale testing. As the global population continues to age, innovations like this could be crucial for maintaining quality healthcare access.
This breakthrough represents more than just a technical achievement—it’s a significant step toward more patient-centered care that reduces the burden of treatment while maintaining therapeutic efficacy. For millions of patients who rely on antibody treatments, the promise of receiving their life-saving medications through a simple injection rather than hours-long hospital visits could dramatically improve their quality of life.
Leave a Reply